A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Mar 24, 2015

ASTELLAS AND MEDIVATION ANNOUNCE NEW ENZALUTAMIDE DATA PRESENTED DURING PLENARY PRESENTATIONS AT THE 2015 EUROPEAN ASSOCIATION OF UROLOGY CONGRESS

Read more
Mar 20, 2015

ANNOUNCEMENT OF MARKETING APPROVAL SUBMISSION TO MHLW (JAPAN) FOR LDL CHOLESTEROL-LOWERING MEDICATION EVOLOCUMAB

Read more
Mar 17, 2015

Astellas Submits Supplemental New Drug Application for Kiklin® Capsules, a Treatment for Hyperphosphatemia, in Japan

Tokyo, March 17, 2015 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) today announced that it submitted a supplemental new drug application for...

Read more
Mar 16, 2015

Notice of Completion of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more
Mar 9, 2015

Astellas Receives FDA Approval for CRESEMBA® (isavuconazonium sulfate) for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis

NORTHBROOK, Ill., March 6th, 2015, – Astellas today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for the use of CRESEMBA®...

Read more

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts